Ritter Pharmaceuticals (NASDAQ:RTTR)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Wednesday. They presently have a $15.00 price objective on the biotechnology company’s stock.
The analysts wrote, “Valuation and risks to price target achievement. We maintain our Buy rating and $4.30. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, topsalysin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.””
A number of other brokerages also recently commented on RTTR. ValuEngine raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Tuesday, May 8th.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15). research analysts expect that Ritter Pharmaceuticals will post -2.89 earnings per share for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Recommended Story: Technical Analysis
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.